195 related articles for article (PubMed ID: 9723360)
1. Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
Markell MS; Homel P; Sumrani N; Hong JH; Distant DA; Miles AM; Sommer BG; Friedman EA
Transplant Proc; 1998 Aug; 30(5):1980-2. PubMed ID: 9723360
[No Abstract] [Full Text] [Related]
2. Variability of Sandimmune pharmacokinetics in renal transplant patients.
Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
[No Abstract] [Full Text] [Related]
3. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
Opelz G
Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
[No Abstract] [Full Text] [Related]
4. Early cyclosporine concentration as predictor of graft survival in cadaveric renal transplantation.
Salmela K; Kyllönen L
Transplant Proc; 2001 Jun; 33(4):2441-3. PubMed ID: 11406202
[No Abstract] [Full Text] [Related]
5. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
[No Abstract] [Full Text] [Related]
6. Trough cyclosporine concentration variability.
Savoldi S; Maiorca R; Chiappini R; Scolari F; Sandrini S
Transplant Proc; 1998 Aug; 30(5):1642-4. PubMed ID: 9723225
[No Abstract] [Full Text] [Related]
7. Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft.
Mizuno Y; Kikuchi H; Fujimori K; Doi H; Orii T; Ohkohchi N; Satomi S
Transplant Proc; 2000 Nov; 32(7):1677-8. PubMed ID: 11119888
[No Abstract] [Full Text] [Related]
8. Persistent proteinuria as a useful parameter to distinguish between chronic renal rejection and cyclosporin nephrotoxicity.
Fernández-Fresnedo G; Escallada R; Rodrigo E; Piñera C; de Francisco AL; Ruiz JC; Cotorruelo JG; Zubimendi JA; Arias M
Transplant Proc; 2002 Feb; 34(1):365-6. PubMed ID: 11959329
[No Abstract] [Full Text] [Related]
9. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function.
Waiser J; Slowinski T; Brinker-Paschke A; Budde K; Schreiber M; Böhler T; Hauser I; Neumayer HH
Nephrol Dial Transplant; 2002 Jul; 17(7):1310-7. PubMed ID: 12105257
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine trough levels in diabetic and nondiabetic renal transplant patients.
Wadhawan S; Jauhari H; Singh S
Transplant Proc; 2000 Nov; 32(7):1683-4. PubMed ID: 11119891
[No Abstract] [Full Text] [Related]
11. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
[No Abstract] [Full Text] [Related]
12. Effects of calcium channel blockers in renal allograft patients receiving cyclosporine.
Suh BY; Kwun OS; Kwun KB
Transplant Proc; 1998 Nov; 30(7):3558-60. PubMed ID: 9838558
[No Abstract] [Full Text] [Related]
13. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
Vathsala A; Lu YM
Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
[No Abstract] [Full Text] [Related]
14. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
[No Abstract] [Full Text] [Related]
15. Cyclosporine blood concentration at 2 hours (C(2)) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients--a four-year follow-up.
Baczkowska T; Serafinowicz A; Kukuła K; Nowacka-Cieciura E; Cieciura T; Deborska D; Gałazka Z; Rowiński W; Szmidt J; Durlik M; Lao M
Transplant Proc; 2002 Mar; 34(2):556-7. PubMed ID: 12009622
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
Gaspari F; Anedda MF; Signorini O; Amuchastegui SC; Perico N; Remuzzi G
Transplant Proc; 1998 Aug; 30(5):1654-5. PubMed ID: 9723229
[No Abstract] [Full Text] [Related]
17. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
Crocker J; Renton K; Wade A; McLellan H; Acott P
Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
[No Abstract] [Full Text] [Related]
18. Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years.
Gracida C; Melchor JL
Transplant Proc; 1998 Aug; 30(5):1742-3. PubMed ID: 9723262
[No Abstract] [Full Text] [Related]
19. To keep a stable therapeutic level of cyclosporine during the early posttransplant period is important in graft survival.
Ahn MS; Ha J; Yun IJ; Kim S; Lee JS; Kim S; Han JS; Ahn C; Choi Y; Cheong HI; Kim ST; Kim SJ
Transplant Proc; 1996 Jun; 28(3):1316-7. PubMed ID: 8658675
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of abbreviated AUC of cyclosporine in renal allograft recipients in a Pakistani population.
Zafar MN; Abbas K; Naqvi A; Rizvi A
Transplant Proc; 1999 Dec; 31(8):3304. PubMed ID: 10616486
[No Abstract] [Full Text] [Related]
[Next] [New Search]
